Sun Pharma's partner announced that Vibozilimod (SCD-044) did not achieve its primary endpoints in Phase 2 trials for treating psoriasis and eczema. Further evaluation of the next steps will be undertaken.
AI Assistant
Sun Pharma Advanced Research Company Ltd
2025
Announcement
Find Answers
Ask about any part of the document to get insights, explanations, or key details.